格隆汇2月25日丨长风药业(02652.HK)公告，2月25日耗资123.2万港元回购3.3万股。 ...

智通财经APP讯，长风药业(02652)发布公告，于2026年2月25日，该公司斥资123.23万港元回购3.3万 股。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02652 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | 每股發行/出售價 (註4) | 已發行股份總數 | | 於下列日期開始時的結存(註1) | 2026年2月24日 | 301,833,586 | | 390,000 | | 302,223,586 | | 1). 購回股份 (股份被持作庫存股份) | | -33,000 | 0.0109 % ...

长风药业(02652)早盘涨超5%，截至发稿，涨5.14%，报38.8港元，成交额685.47万港元。 消息面上，2月24日，长风药业发布公告，本公司自主研发的吸入粉雾剂候选药物ICF004(产品)的新药 临床试验(IND)申请(该申请)已获中国国家药品监督管理局(NMPA)受理。该申请的受理是本公司创新药 研发进程中的重要里程碑，并进一步体现了本公司在复杂呼吸制剂及精准递送平台方面的转化潜力。 据了解，ICF004拟用于治疗进行性纤维化性间质性肺疾病(PF-ILD)，该疾病领域覆盖特发性肺纤维化 (IPF)及进行性肺纤维化(PPF)等严重威胁患者生存的适应症。锚定PF-ILD未满足需求，ICF004的研发逻 辑立足于"疗效—耐受性"临床矛盾，在现有治疗基础上探索新的递送与作用路径，以期改善治疗窗口和 患者获益。 ...

Core Viewpoint - Changfeng Pharmaceutical (02652) experienced a stock price increase of over 5%, reaching HKD 38.8 with a trading volume of HKD 6.8547 million following the acceptance of its IND application for the inhalation powder candidate drug ICF004 by the NMPA [1] Group 1: Company Developments - The IND application for ICF004, a self-developed inhalation powder candidate drug, has been accepted by the National Medical Products Administration (NMPA) of China [1] - This acceptance marks a significant milestone in the company's innovative drug development process, highlighting its potential in complex respiratory formulations and precision delivery platforms [1] - ICF004 is intended for the treatment of progressive fibrosing interstitial lung disease (PF-ILD), which includes indications such as idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), both of which pose serious threats to patient survival [1] Group 2: Research and Development Focus - The development logic of ICF004 is based on addressing the unmet needs in the PF-ILD field, focusing on the clinical contradiction of "efficacy-tolerability" [1] - The company aims to explore new delivery and action pathways on the existing treatment basis to improve the therapeutic window and patient benefits [1]

Investment Rating - The report indicates a positive investment outlook for Changfeng Pharmaceutical, particularly due to the acceptance of the IND application for ICF004, a first-in-class inhalation powder for treating pulmonary fibrosis [2][5]. Core Insights - Changfeng Pharmaceutical's ICF004 has received IND acceptance, marking a significant milestone in the development of new treatments for progressive fibrosing interstitial lung disease (PF-ILD) [2][5]. - The drug aims to address unmet clinical needs in PF-ILD, which includes idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), both of which severely threaten patient survival [4][9]. - ICF004's unique delivery method allows for targeted lung delivery, achieving a lung/blood exposure ratio exceeding 100 times, which may enhance efficacy while minimizing systemic exposure [10][11]. Summary by Sections Section 1: Drug Development and Mechanism - ICF004 is classified as a first-in-class chemical drug candidate, designed for inhalation delivery to treat PF-ILD [4]. - The drug's development focuses on exploring mechanisms related to fibrosis, including inflammation and oxidative stress, aiming for a novel treatment approach distinct from existing oral therapies [5]. Section 2: Clinical Need and Current Treatments - PF-ILD is characterized by worsening respiratory symptoms and irreversible decline in lung function, with a median survival of approximately 2.8 years for IPF patients and a 5-year survival rate below 40% [6]. - Current treatment options are limited to two oral medications, which, while they can slow lung function decline, have significant side effects and limited survival benefits [7][8]. Section 3: Delivery and Pharmacokinetics - ICF004's inhalation delivery method is designed to target the lung lesions directly, showing a significant pharmacokinetic profile with over 100 times higher exposure in the lungs compared to the bloodstream [10][11]. - Preclinical studies suggest potential anti-fibrotic activity, although further clinical trials are necessary to confirm efficacy and safety in humans [12][13]. Section 4: Company Capabilities and Future Plans - Changfeng Pharmaceutical has a comprehensive capability in developing complex formulations and precision delivery technologies, which supports its innovative drug development strategy [14][16]. - The advancement of ICF004 reflects the company's ability to translate high-barrier delivery and formulation platforms into clinical development assets, with plans to actively pursue further clinical development while adhering to regulatory requirements [17].

Core Viewpoint - Changfeng Pharmaceutical's candidate drug ICF004 for treating pulmonary fibrosis has received acceptance for clinical trial application from the NMPA, marking a significant milestone in its drug development process [4][5]. Group 1: Drug Development Progress - ICF004 is a class 1 chemical drug candidate designed as an inhalation powder for treating progressive fibrosing interstitial lung disease (PF-ILD), which includes idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) [6][8]. - The acceptance of the IND indicates that ICF004 has passed preliminary regulatory review and is now entering the clinical trial preparation phase [7][8]. - The drug's development focuses on exploring mechanisms related to fibrosis, particularly inflammation, oxidative stress, and fibroblast activation, aiming to provide a novel treatment pathway distinct from existing oral therapies [7][8]. Group 2: Clinical Need and Market Potential - PF-ILD is characterized by worsening respiratory symptoms and irreversible decline in lung function, with a median survival of approximately 2.8 years for IPF patients and a 5-year survival rate of less than 40% [8]. - Current treatments for IPF are limited to two approved oral medications, which, while they can slow lung function decline, have limited survival benefits and significant side effects [8]. - ICF004 addresses an unmet clinical need, positioning it as a potentially groundbreaking "first-in-class" candidate drug [8]. Group 3: Pharmacokinetics and Delivery Mechanism - ICF004 utilizes an inhalation powder delivery method, targeting direct delivery to lung lesions, with preclinical studies showing a significant difference in drug exposure between lung tissue and systemic circulation, with a lung/blood exposure ratio exceeding 100 times [9][12]. - This pharmacokinetic profile suggests the potential for high local concentration in the lungs while minimizing systemic exposure, which may enhance the balance between efficacy and safety [12]. Group 4: Company Capabilities and Future Plans - Changfeng Pharmaceutical has capabilities in complex formulations, small nucleic acids, liposomal drugs, and precision delivery technologies, with a focus on respiratory diseases [14]. - The advancement of ICF004 reflects the company's ability to integrate complex formulations and delivery systems with unmet clinical needs, providing a methodological and organizational reference for future innovative projects [14]. - The company plans to actively promote the subsequent clinical development of ICF004 in accordance with NMPA regulations, evaluating strategies for independent advancement and collaborative development based on clinical progress and resource allocation [14].

长风药业(02652)发布公告，该公司于2026年2月24日斥资99.74万港元回购2.7万股股份，每股回购价格 为36.6-37.18港元。 ...

格隆汇2月24日丨长风药业(02652.HK)发布公告，2026年2月24日耗资99.74万港元回购2.7万股，回购价 格每股36.6-37.18港元。 ...

智通财经APP讯，长风药业(02652)发布公告，该公司于2026年2月24日斥资99.74万港元回购2.7万股股 份，每股回购价格为36.6-37.18港元。 ...